ACC: Mavacamten Efficacious for Adolescents With Obstructive Hypertrophic Cardiomyopathy

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Amazon Big Spring Sale - Up to 40% off

Medically reviewed by Carmen Pope, BPharm. Last updated on April 1, 2026.

via HealthDay

WEDNESDAY, April 1, 2026 -- Mavacamten, the first-in-class cardiac myosin inhibitor approved for treatment of symptomatic adults with obstructive hypertrophic cardiomyopathy (HCM), is efficacious for adolescents with obstructive HCM, according to a study published online March 29 in the New England Journal of Medicine to coincide with the annual meeting of the American College of Cardiology, held from March 28 to 30 in New Orleans.

Joseph W. Rossano, M.D., from the Children's Hospital of Philadelphia, and colleagues conducted a randomized international study assessing the efficacy and safety of mavacamten in adolescents (aged 12 to <18 years) with obstructive HCM. After five weeks of screening, 44 participants were randomly assigned to either mavacamten (2.5 or 5 mg/day based on body weight) or placebo for 28 weeks.

The researchers found that participants receiving mavacamten had a substantial improvement in terms of the change in Valsalva left ventricular outflow tract (LVOT) gradient from baseline to week 28, with average decreases of 48.5 and 0.5 mmHg in the mavacamten and placebo groups, respectively. Significant improvements in favor of mavacamten were also seen in secondary end points, including change in resting LVOT gradient, maximal left ventricular wall thickness, peak oxygen consumption, and symptom measures such as fatigue and shortness of breath. Troponin and peptide levels decreased in those taking mavacamten and increased in those taking placebo.

"Beyond symptom relief, there's a signal that this may be favorably remodeling the heart, which could improve the natural history of the disease," Rossano said in a statement. "This suggests that it could be important to start children on this therapy when they’re young, before they've had many decades of ongoing injury to the heart from the obstruction."

The study was funded by Bristol Myers Squibb, manufacturer of mavacamten.

Abstract/Full Text (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-02 01:56

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords